Abstract 15326: Intramyocardial Injection of Autologous Bone Marrow Cells in Chronic Myocardial Ischemia is Safe During 5 Year Follow Up
Background: Intramyocardial injection of bone marrow cells (BMC) in patients with ischemic heart disease has shown to be safe during short term follow-up. However, the safety data on long term follow-up is limited. We assessed the safety in chronic myocardial ischemia patients up to 5 years after intramyocardial BMC injections.
Methods and Results: A total of 120 patients (age 64±9 years, male 88%) with chronic myocardial ischemia and refractory angina pectoris underwent intramyocardial BMC injection, using the NOGA system. In 1 patient pericardial effusion developed 1 day after the injection procedure which was treated successfully. No other procedural-related events occurred during short term and 5 years follow-up. Clinical events were assessed at the outpatient clinic on a yearly basis and are shown in the figure. Results demonstrate an event free survival for mortality of 84.5%, myocardial infarction of 91.0%, revascularization of 79.3% and admission for heart failure of 98.8% during 5 years follow-up.
Conclusion: The present study shows that intramyocardial bone marrow cells injection in patients with chronic myocardial ischemia and refractory angina pectoris is safe during long term follow-up.
- © 2012 by American Heart Association, Inc.